HYPE: Medicinal nicotine replacement improves the chance of quitting smoking.
But what does the evidence actually show?
Yes. High-quality evidence shows that licensed nicotine replacement therapy improves long-term quit rates. Combining a patch with a fast-acting form works better than one form alone, while the best choice still depends on the person.
What is the hype?
Using nicotine to stop smoking can seem contradictory because nicotine causes dependence. The treatment aims to reduce withdrawal while removing cigarette smoke exposure. That is a different purpose and risk comparison from starting nicotine for focus when you do not smoke.
The main review measured sustained quitting
Cochrane's primary comparison included 133 studies and 64,640 people. Nicotine replacement increased the relative chance of abstinence at six months or longer by about 55% compared with placebo or no NRT. This does not mean that 55% of users quit. The absolute gain depends on the starting quit rate and support available. [1]
What relative improvement means in practice
For illustration, if 10 of 100 people would quit in a comparison group, a relative risk of 1.55 corresponds to roughly 15 or 16 of 100 with treatment. That is an arithmetic example, not a prediction for a particular service or smoker. Reporting an absolute number without a baseline would be misleading.
Combination therapy has additional evidence
A 2023 Cochrane review found high-certainty evidence that a patch plus a fast-acting form produced higher long-term quit rates than a single NRT form. In 16 studies with 12,169 participants, the relative risk was 1.27. This is an additional relative comparison between NRT strategies, not a 27-percentage-point increase in success. [2]
Safety and product identity matter
Local irritation, such as skin problems with patches or mouth irritation with oral products, can occur. Serious events were uncommon in the evidence reviewed. NHS guidance distinguishes licensed NRT from nicotine pouches, which are not licensed stop-smoking products in the UK. Sharing nicotine as an ingredient does not establish the same evidence or intended use. [1] [3]
The catch: limitations and uncertainty
Most trials recruited adults motivated to quit, often smoking regularly at baseline. Not every dose, duration or combination has equally strong comparative evidence. Treatment reduces withdrawal but does not remove every behavioural or social driver of smoking, and relapse does not mean that the evidence or the person has failed.
What this means for you
Ask a pharmacist, clinician or stop-smoking service about a suitable product and how to use it effectively. Behavioural support can complement medication. If pregnant or managing a medical condition, seek product-specific advice. Judge success by avoiding smoking and maintaining progress rather than assuming that an unaided attempt is more legitimate.
Nicotine replacement is a well-supported quitting aid when used for the right purpose.
Research & Sources
1. Hartmann-Boyce et al. (2018). Nicotine replacement therapy versus control for smoking cessation.
Cochrane review; sustained abstinence comparison.
Read the original source ↗2. Theodoulou et al. (2023). Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation.
Cochrane review; combination versus single-form NRT.
Read the original source ↗3. NHS Better Health. Quit smoking with nicotine replacement therapies.
Current UK practical guidance and distinction from pouches.
Read the original source ↗Evidence reviewed: October 2026
This targeted editorial review considered sources available in October 2026. It is not an exhaustive systematic review. Source access and indirect evidence are identified above. Evidence vs Hype provides education, not individual diagnosis or treatment. Original AI-generated featured artwork is conceptual and does not demonstrate a study result. No commercial product was selected or endorsed.